AGIOS PHARMACEUTICALS, INC. Allowance for Doubtful Accounts, Premiums and Other Receivables
AGIOS PHARMACEUTICALS, INC. (AGIO) had Allowance for Doubtful Accounts, Premiums and Other Receivables of $0 as of 2017-12-31, per its 10-K filed 2018-02-14.
Discontinued › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables · last filed 2018-02-14
- 2017-12-31: Allowance for Doubtful Accounts, Premiums and Other Receivables $0.00.
- 2016-12-31: Allowance for Doubtful Accounts, Premiums and Other Receivables $0.00.
| Period end | Allowance for Doubtful Accounts, Premiums and Other Receivables |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-14 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |